What is DAIZ?
DAIZ is a global leader in the development of plant-based protein, distinguished by its proprietary Ochiai Germination Method (OGM). This breakthrough technology, refined over 25 years of rigorous research, allows for the custom design of raw materials that naturally replicate the taste and texture of meat. Beyond its flagship Miracle Meat product, which is currently integrated into the supply chains of major global food manufacturers, DAIZ is pioneering the application of OGM in drug discovery. By integrating artificial intelligence with plant-based secondary metabolites, the company is exploring novel chemical spaces for therapeutic research, positioning itself at the intersection of food technology and advanced pharmacology.
How much funding has DAIZ raised?
DAIZ has raised a total of $47M across 1 funding round:
Series C
$47M
Series C (2023): $47M with participation from Mitsubishi UFJ Capital, Roquette Frères, The Kagoshima Bank, and Miyoshi Oil & Fat
Key Investors in DAIZ
Mitsubishi UFJ Capital
A prominent venture capital firm that provides deep market access and financial expertise, having supported over 1,000 companies throughout their growth cycles.
Roquette Frères
A global leader in plant-based ingredients and pharmaceutical solutions, focusing on sustainable resource use and high-performance nutrition.
The Kagoshima Bank
A long-standing financial institution providing essential banking, leasing, and credit services to support regional and corporate development.
What's next for DAIZ?
With the support of this major enterprise-level funding, DAIZ is poised to transition from a specialized technology developer to a dominant force in the global food and biotech markets. The strategic roadmap includes scaling the production of Miracle Meat to meet the rising demand for clean-label, plant-based alternatives among international food conglomerates. Simultaneously, the company will intensify its R&D efforts in the drug discovery vertical, utilizing its OGM platform to identify new organic molecules for pharmaceutical applications. This dual-track growth strategy, supported by a robust capital base, ensures that DAIZ remains at the forefront of sustainable innovation, effectively bridging the gap between nutritional science and modern medicine.
See full DAIZ company page
